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To review the epidemiology of nosocomial extended spectrum -lactamase-producing
Enterobacteriaceae in Latin America, a systematic search of the biomedical literature (PubMed)
was performed for articles published since 2005. Rates of nosocomial infections caused
by  extended spectrum -lactamase-producing Enterobacteriaceae in Latin America have
increased since 2005. Up to 32% of Escherichia coli and up to 58% of Klebsiella pneumoniae
isolates are extended spectrum -lactamase-positive, rates that are higher than in other
world regions. From a region-wide perspective, 11–25% of E. coli isolates and 45–53% of K.
pneumoniae isolates were nonsusceptible to third-generation cephalosporins. At the coun-
try  level, there was a wide range in Enterobacteriaceae resistance rates to third-generation
cephalosporins, with especially high rates of resistance to E. coli in Guatemala, Honduras,
and  Mexico, and high resistance rates to Klebsiella spp. in Argentina, Brazil, Chile, Guatemala,
Honduras, and Paraguay. Susceptibility of extended spectrum -lactamase-producing Entero-
bacteriaceae to cefepime, ﬂuoroquinolones, ampicillin/sulbactam, aminoglycosides, and
piperacillin/tazobactam has also been compromised, leaving the carbapenems, tigecycline,
and  colistin as the only antibiotics with >90% susceptibility rates. There is a steady increase
in  the prevalence and types of extended spectrum -lactamases produced by Enterobac-
teriaceae isolates in Latin American hospitals (particularly CTX-Ms), suggesting endemicconditions overlaid by clonal outbreaks. Appropriate treatment decisions and infectioncontrol strategies informe
anisms of resistance are r
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Introduction
Health care-associated infections (HAIs) are particularly chal-
lenging in developing countries such as those of Latin America
owing to their far higher rate of occurrence than in devel-
oped countries. For instance, the World Health Organization
reported that the pooled prevalence of hospital-wide HAIs
between 1995 and 2010 in low- and middle-income countries
was 10.1 per 100 patients (95% conﬁdence interval [CI],
8.4–12.2), which compares unfavorably with the correspond-
ing rate in high-income countries (7.6 episodes per 100
patients; 95% CI, 6.9–8.5).1 Most HAIs in developed and devel-
oping countries are by Gram-negative bacteria, predominantly
species and subspecies from the Enterobacteriaceae family fol-
lowed by nonfermenters such as Pseudomonas aeruginosa and
Acinetobacter baumannii.1–4 The capacity of health care profes-
sionals to manage nosocomial infections by Enterobacteriaceae
has diminished over the last decade because of the emer-
gence and widespread dissemination of multidrug-resistant
phenotypes.2,5–8
Production of -lactamases is the primary mecha-
nism of -lactam resistance in these pathogens.9–15 ESBL,
extended spectrum -lactamase (ESBLs) can confer resis-
tance to penicillins, ﬁrst-, second-, and third-generation
cephalosporins, and aztreonam (but not the cephamycins
such as cefoxitin or carbapenems), and are usually inhibited
by -lactamase inhibitors such as clavulanic acid.15 Most
ESBLs can also hydrolyze fourth-generation cephalosporins
(e.g., cefepime or cefpirome).16,17 It is important to note
that AmpC -lactamases differ from typical ESBLs in that
AmpC -lactamases, besides hydrolyzing third-generation
cephalosporins, are not inhibited by -lactamase inhibitors.15
Furthermore, Enterobacteriaceae harboring ESBLs are often
co-resistant to ﬂuoroquinolones, aminoglycosides, and
trimethoprim/sulfamethoxazole.15,18 Thus, infections by
these multidrug-resistant pathogens are a major public health
threat, as there are limited treatment options available.
The purpose of this review is to provide an updated epi-
demiology of ESBL-producing Enterobacteriaceae in the Latin
American hospital setting, with a focus on antimicrobial sus-
ceptibilities of Escherichia coli and Klebsiella pneumoniae strains
throughout the region. We include in this review data from the
Spanish- and Portuguese-speaking countries of the Americas,
including Mexico.
Background:  emergence  of  extended  spectrum
-lactamase-producing  Enterobacteriaceae  in
Latin  America  before  2005
During the period from 1987 to 1989, K. pneumoniae express-
ing sulfhydryl variant (SHV)-5 and SHV-2 were responsible
for infection outbreaks in a Buenos Aires intensive care unit
(ICU).14 Retrospective analysis of a lyophilized strain of K.
pneumoniae recovered in 1982 from the urine of a patient
with an indwelling urinary catheter detected SHV-5, making
this the earliest detected ESBL-producing bacterium in South
America.14,19 Cefotaxime-resistant (CTX-M) -lactamase was
ﬁrst described in an outbreak of neonatal infection with
Salmonella typhymurium during 1989 in Argentina, Bolivia, and 1 4;1  8(4):421–433
Paraguay.14 Further outbreaks of infections in neonates caused
by ESBL-producing Klebsiella spp. were reported in the late
1990s in Mexico and Brazil.20,21
By the late 1990s, ESBL expression by Enterobacteriaceae
in Latin American hospitals became endemic. During SEN-
TRY antimicrobial surveillance conducted between 1997 and
2002, the prevalence of Klebsiella spp. expressing ESBLs in
blood cultures from hospitalized patients was greater in Latin
America than in Europe and North America (43% vs. 22%
and 6%, respectively, p < 0.001).9 SENTRY data for urine iso-
lates revealed that ∼45% of Klebsiella spp. exhibited an ESBL
phenotype in 2000 (compared with ∼30% during 1997–1999)
and ∼5% of E. coli exhibited an ESBL phenotype during both
testing periods.13 The percentage of Enterobacteriaceae produc-
ing ESBLs was also very high in Brazilian hospitals (SENTRY,
1997–1999), with 50% of all K. pneumoniae isolates and 9% of all
E. coli isolates suspected of harboring ESBLs.22 Over  a slightly
later timeframe, ﬁndings of the Meropenem Yearly Suscepti-
bility Test Information Collection (MYSTIC) study (1997–2003)
showed that 52% of K. pneumoniae isolates from Latin America
(vs. 12% from North America), 18% of E. coli isolates (vs. 8%
from North America), and 6% of Proteus mirabilis isolates (vs.
4% from North America) were ESBL-positive.23
CTX-M-type -lactamases eventually replaced TEM and
SHV variants as the most common type of ESBL globally.18,24
In 2000, CTX-M-2 was the most prevalent type of ESBL in Latin
America (especially in the southern part of the continent),25
and in 2002, CTX-M-12 from a strain of K. pneumoniae was
detected in Colombia, representing the ﬁrst description of
a CTX-M in this country.26 While ESBLs are found pre-
dominantly in Klebsiella spp. and E. coli,  they have also
been described in other genera of Enterobacteriaceae including
species of Citrobacter,  Serratia, Proteus, Morganella,  Salmonella,
and Enterobacter.14
Methods
To review the published clinical data relating to epidemiol-
ogy of ESBL-producing Enterobacteriaceae in the Latin American
hospital setting, a systematic search of the biomedical lit-
erature was conducted. Medline (via PubMed) was searched
limited by the dates 1 January 2005 to 15 July 2013 for articles
using the following terms and Boolean logic: (Extended spec-
trum beta lactamase OR ESBL) AND (Enterobacteriaceae OR coli
OR Klebsiella OR Shigella OR Salmonella OR Proteus) AND (“Latin
America” OR “South America” OR “Central America” OR Mex-
ico OR Guatemala OR Honduras OR Nicaragua OR “Costa Rica”
OR Cuba OR “Dominican Republic” OR Panama OR Colombia
OR Venezuela OR Guyana OR Suriname OR “French Guiana” OR
Brazil OR Ecuador OR Peru OR Bolivia OR Paraguay OR Uruguay
OR Chile OR Argentina). Selected additional references were
identiﬁed by authors.
Prevalence  and  type  of  extended  spectrum
-lactamasesRegional  data
Several regional surveillance studies monitor drug resistance
in Latin America, most with a small number of participating
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Table 1 – Number of study sites by country for key surveillance reports.
Country Surveillance program and collection period
SMART27 SMART28 SMART29 SMART30 TEST31 TEST32 SENTRY33 PAHO34,a PAHO35,a
2004 2005 2008 2008–2009 2004–2006 2004–2010 2008–2010 2006 2009
Argentina 3 2 2 2 9 12 2 59 72
Bolivia 19 30
Brazil 3 2 5 1 1 3 4
Chile 2 2 2 2 5 2
Colombia 1 3 2 14 147
Dominican Republic 1 1 14 14
Ecuador 1 1 21 22
El Salvador 1 33 33
Guatemala 1 1 1 1 4 6 5
Honduras 2 4 7
Mexico 2 2 3 4 1 15 2
Nicaragua 1 10 11
Panama 1 1 1 1 2 24 24
Paraguay 8 21
Peru 1 2 22 40
Puerto Rico 2 2 1
Venezuela 1 3 3 6 34 24
PAHO, Pan-American Health Organization; SMART, Study for Monitoring Antimicrobial Resistance Trends; TEST, Tigecycline Evaluation and
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xtended spectrum -lactamase; SMART, Study for Monitoring A
valuation and Surveillance Trial.settings.
than in other world regions (Fig. 1).8,27,28,31,36 Similarly, only
the Asia/Paciﬁc region had higher rates of ESBL production in
E. coli. 8,27,28,31,36 Furthermore, prevalence of ESBL-producing
E. coli and Klebsiella spp. appears to have steadily increased
over the last decade (Table 2).8,27–33,36 A greater proportion
of Klebsiella spp. than E. coli produce ESBLs, although ESBL
production by E. coli has increased since the period before 2005.
SMART 20042009-2010 SMART 2005 TEST 2004-2006 DISN 2007
Europe Asia/Pacific
Klebsiella spp.
19
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16
4444
8
13 13
8
8
9
5
28 28
23
27
*
*
oniae isolates in the SMART and TEST antimicrobial
Doripenem International Surveillance Network; ESBL,
ntimicrobial Resistance Trends; TEST, Tigecycline
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Table 2 – Temporal prevalences of healthcare-acquired ESBL-positive Enterobacteriaceae in hospitals of Latin America.
Surveillance program Collection period Anatomical collection site Proportion ESBL-positive
(total no. isolates)
E. coli Klebsiella spp.
SMART27 2004 Intra-abdominal 12% 28%
SMART28 2005 Intra-abdominal 16% (395) 27% (121)
TESTa,31 2004–2006 Blood, respiratory tract, urine,
skin, wound, ﬂuids and other
deﬁned sources
14%  (326) 44% (282)b
TEST32 2004–2010 Blood, respiratory tract, urine,
skin, wound, ﬂuids
24%  (3581) 35% (2962)b
DISN8 2007 Blood, respiratory tract, skin
and skin structure, urine
14% (493) 44% (350)b
SMART29 2008 Intra-abdominal 27% (504) 38% (151)b
SMART30 2008–2009 Intra-abdominal 24% (1366) NR
SENTRY33 2008–2010 Blood, skin and soft tissue,
lower respiratory tract
25%  (1517) 53% (1052)
SMARTc,36 2009–2010 Urine 23%
ESBL, extended spectrum -lactamase; DISN, Doripenem International Surveillance Network; NR, not reported; SMART, Study for Monitoring
Antimicrobial Resistance Trends; TEST, Tigecycline Evaluation and Surveillance Trial.
a
s locaMost data were collected from intensive care units.
b K. pneumoniae only.
c Data collected from 15 sites in Latin America; countries where site
Country-speciﬁc  data
Surveillance  studies
In the SENTRY 2008–2010, SMART 2008–2009, and TEST
2004–2010 reports, the frequencies of E. coli producing ESBLs
were highest in Chile, Ecuador, Guatemala, Honduras, and
Mexico (Fig. 2a).30,32,33 Among Klebsiella spp., ESBL phenotype
rates of 50% or greater were observed in Argentina, Brazil,
Chile, and Honduras (Fig. 2b).32,33
Cohort  studies
As in the surveillance studies, independent cohort data
revealed that a greater proportion of K. pneumoniae than
E. coli clinical isolates produce ESBLs throughout the con-
tinent (Fig. 3).37–48 The range of ESBL production among K.
pneumoniae isolates varied from 24% (in Cuba, 2009–2010)44
to 58% (in Curitiba, Brazil, 2003–2004)46 whereas ESBL pro-
duction among E. coli isolates varied from 7% (in southern
Brazil)45 to 32% (in Sonoro, Mexico, 2008–2009).42 Care must
be taken when interpreting these data because of inter-study
differences with respect to the time, method (i.e., consecu-
tive or random), and anatomical site of sample collection, as
well as the microbiological techniques and standards used.
Nevertheless, data collected by independent cohort studies
on the frequency of ESBL production among E. coli clinical
isolates (Fig. 3) compared favorably with data collected by
SMART, SENTRY, and TEST (Fig. 2a) for Brazil (range, 7–24%
vs. 13–17%, respectively), Mexico (16–32% vs. 38–48%) and
Venezuela (16–27% vs 15–30%). Regarding the frequency of
ESBL production among K. pneumoniae clinical isolates, gen-
eral agreement was observed between independent cohort
(Fig. 3) and surveillance data (Fig. 2b) for Brazil (44–58% vs.
49–50%, respectively), and Mexico (27–36% vs. 25–33%), but
not Venezuela (46–48% vs. 17%). Limited prevalence data were
available for Bolivia (Santa Cruz de la Sierra, 2004) whereinted not speciﬁed.36
150–642 (23%) consecutively collected Gram-negative isolates
were putative ESBL producers, but this statistic encompassed
strains of P. aeruginosa and Acinetobacter spp. in addition to
Enterobacteriaceae.49
The molecular characteristics of the ESBL isolates detected
in surveillance studies were not described in those publica-
tions. Most of our knowledge about speciﬁc ESBLs circulating
in Latin American hospitals comes from independent cohort
studies. Fig. 3 shows that CTX-Ms have inﬁltrated most
countries to various extents, with CTX-M-15 commonly found
in the northern part of the continent. The endemicity of CTX-
M-15 is challenging because this enzyme, unlike other ESBLs,
can hydrolyze ceftazidime.50 CTX-M-2 was the most common
subtype in Argentina (52% of 50 ESBL producers), and data
indicated emergence of CTX-M-15 (38%) along with CTX-M-
8 (2%) and CTX-M-9 (6%).48 SHV enzymes (particularly SHV-5
and SHV-12) were highly prevalent in Mexico, Colombia, and
Brazil (Fig. 3).
These prevalence ﬁndings are supported by results of
studies that examined the genotype distribution among
ESBL producers. Of 127 ESBL-producing Enterobacteriaceae iso-
lated over one year from inpatients and outpatients at a
public teaching hospital at São Paulo, Brazil, blaCTX-M and
blaSHV were highly prevalent (in 34% and 63% of strains,
respectively).51 In Colombia (Bogota, 2003–2005), computa-
tional sequencing analysis revealed that CTX-M-12 (56%)
and SHV-12 (33%) were the most prevalent ESBLs produced
among 177 K. pneumoniae isolates harboring bla genes.52 In
Bolivia, blaCTX-M-2 (71%), and to a lesser extent blaCTX-M-43
(21%), were the most prevalent genes encoding ESBL pro-
duction in 150 Gram-negative clinical isolates collected from
four hospitals in Santa Cruz de la Sierra during a 4-month
49period in 2004. In addition, blaPER-2 was reported among
31% of 122 ESBL+ K. pneumoniae isolates collected in 10 hos-
pitals in Chile in 1998–2004 (40% were blaCTX-M and 13% were
blaGES),53 and 15% of 47 ESBL+ K. pneumoniae isolates collected
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From a regional perspective, E. coli strains were
more  often susceptible (75–89%) to third-generation
cephalosporins than strains of K. pneumoniae (47–55%,
referring to strains that were not distinguished as ESBL+
or ESBL−).28–33 Susceptibilities of E. coli and K. pneumo-
niae to the fourth-generation cephalosporin cefepime
were not markedly greater than their susceptibilities to
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24% K.  pneumoniae (n=228)
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Fig. 3 – Representation of the frequency of ESBL production (no. of isolates tested) and types of ESBLs produced by
Enterobaceriaceae isolated from Latin American hospitals reporting >100 isolates.37–47 The distribution of ESBLs was not
available for all studies reporting prevalence data. All isolates were  resistant to oxyimino-cephalosporins. ESBL, extended
spectrum -lactamase.
third-generation cephalosporins. As expected, suscepti-
bility to third-generation cephalosporins and cefepime
was much lower among ESBL-positive E. coli and K. pneu-
moniae strains than among ESBL-negative or unspeciﬁed
isolates (Table 3).29–32 Antimicrobial co-resistance was a
recurring feature among these isolates, particularly those
expressing ESBLs. In SENTRY 2008–2010, E. coli (all iso-
lates) were most susceptible to the carbapenems (99–100%),
amikacin (97–100%), piperacillin/tazobactam (82–94%),
and colistin (100%), whereas low rates of susceptibility to
ciproﬂoxacin (35–73%) were observed.33 Susceptibility of
Klebsiella spp. was appreciably lower than that of E. coli
to all of these drug classes, with susceptibility rates of
89–99% for carbapenems, 78–92% for amikacin, 49–81%
for piperacillin/tazobactam, and 95–99% for colistin across
33four countries (Argentina, Brazil, Chile, and Mexico). Even
lower susceptibility rates across the commonly used drug
classes were observed for ESBL-producing E. coli and K.
pneumoniae isolates collected in SMART 2008, 2008–2009,and TEST 2004–2010.29,30,32 Although susceptibility of ESBL-
producing E. coli to carbapenems and tigecycline was
>95% in all of these studies, susceptibility to amikacin
(85–90%), piperacillin/tazobactam (74–80%), and ﬂuoro-
quinolones (12–19%) dropped markedly.29,30,32 Likewise,
susceptibility of ESBL-producing K. pneumoniae to carbapen-
ems (in TEST 2004–2010 and SMART 2008) and tigecycline
(in TEST 2004–2010) was high (≥89%), but susceptibil-
ity was low to amikacin (71–72%), levoﬂoxacin (35–38%),
and piperacillin/tazobactam (34–40%) in both surveillance
studies.29,32
Country-speciﬁc  data
PAHO established a surveillance program in 2000 to col-
lect country-speciﬁc data on selected organisms, both from
nosocomial and community-acquired infections. In 2006 and
2009, there was large variability in Enterobacteriaceae resis-
tance rates to third-generation cephalosporins (cefotaxime
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Table 3 – Proportion of healthcare-acquired Enterobacteriaceae isolates susceptible to third-generation cephalosporins
(and cefepime) in Latin American hospitals.
Pathogen SMART 200528 TEST 2004–200631 TEST 2004–201032 SMART 200829 SMART 2008–200930 SENTRY 2008–201033
E. coli 83–84% (84%a)
n = 395 isolates
82–89% (86%)
n = 326 isolates
82% (94%)
n = 2711
non-ESBL
isolates
96%  (100%)
n > 50
non-ESBL
isolates
94–95% (100%)
n = 1043
non-ESBL
isolates
75–82% (84%)
n = 1517 isolates
1% (28%)
n = 870 ESBL
isolates
2%–28% (7%)
n > 50 ESBL
isolates
1%-21% (12%)
n  = 323 ESBL
isolates
K. pneumoniae NR 53–55% (58%)
n = 282 isolates
77% (88%)
n = 1917
non-ESBL
isolates
96–97% (97%)
n > 50
non-ESBL
isolates
NR  47–55% (59%)
n = 1052
isolatesb
0% (0%)
n = 124 ESBL
K. pneumoniae
isolates
1%  (29%)
n = 1045 ESBL
K. pneumoniae
isolates
2%–28% (7%)
n > 50 ESBL
K. pneumoniae
isolates
S. marcescens NR 77% (82%)
n = 124 isolates
68% (84%)
n = 1126 isolates
NR NR NR
NR, not reported; SMART, Study for Monitoring Antimicrobial Resistance Trends; TEST, Tigecycline Evaluation and Surveillance Trial.
le to 
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(
g
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w
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t
wa Throughout table, ﬁgures in parentheses are proportions susceptib
b Klebsiella spp.
nd ceftazidime), even after accounting for countries with
mall isolate numbers (Table 4)34,35 and few collecting centers
Table 1). In 2009, the resistance rate of E. coli to third-
eneration cephalosporins was highest in Bolivia (37%) and
owest in Nicaragua (0–0.5%; Table 4). PAHO data for K.
neumoniae nosocomial isolates in 2009 showed high levels
f resistance to third-generation cephalosporins, consistent
ith the high prevalence of ESBL-producing strains in Latin
merican countries. The resistance rate of Klebsiella spp. to
hird-generation cephalosporins in 2009 was highest in Peru
66%) and lowest in Nicaragua (0.3%). A high rate of resistance
o cefepime in nosocomial isolates of E. coli and K. pneumoniae
as also reported in PAHO 2009 data (Fig. 4).35 The PAHO data
Table 4 – Findings of the Pan-American Health Organization (PA
Enterobacteriaceae isolates resistant to third-generation cephalo
Country 
E. coli 
2006 2
Argentina 4 (12001) 18 (16
Bolivia 33 (1079) 37 (29
Colombia – 8-9 (96
Dominican Republic 35–40 (516) 23 (30
Ecuador 10–13 (2582) 18–20
El Salvador 4 (1306) 18–32
Guatemala 67–70 (1729) 24 (49
Honduras 21–32 (524) 30–32
Nicaragua 19 (508) 0–0.5 
Panama 4–8 (2522) 8 (304
Paraguay 6–15 (1119) 16 (69
Peru 43–56 (463/282) 32 (14
Venezuela 4–10 (11316) 13–14
a Klebsiella spp.cefepime, a fourth-generation cephalosporin.
for Klebsiella spp. were similar to ﬁndings of the Asociación
Panamericana de Infectología, showing that the proportion
of cefotaxime-resistant strains ranged from 17% (in Ecuador
and Panama) to 60% (in Brazil), resistance rates to ceftazidime
ranged from 13% (in Venezuela) to 40% (in Argentina, Brazil,
and Paraguay), and resistance to cefepime ranged from 10%
(in Colombia) to 50% (in Argentina and Brazil).54
Data collected by the SENTRY Antimicrobial Surveillance
Program between 2008 and 2010 reported country-speciﬁc
data in addition to regional data. They showed that the
susceptibility rate of healthcare-acquired E. coli isolates to
third-generation cephalosporins was low in Mexico (52–53%)
and modest in Argentina, Brazil, and Chile (76–88%).33 Again,
HO) summarizing the frequency of nosocomial
sporins in 2006 and 2009.34,35
% Resistance (total no. isolates)
K. pneumoniae
009 2006 2009
59) 57 (3278)a 58 (1518)
23) 14–47 (646)a 27–50 (984)
07) – 30 (3607)
61) 30 (828) 26 (2510)
 (2736) 14–18 (457) 42–48 (890)
 (2498) 14–15 (421) 46–50 (1007)
21) 68–75 (1456) 52–53 (3001)
 (1273) 44–54 (449) 58–67 (871)
(1081) 65 (312) 0.3 (383)
0) 23–37 (1263) 26–39 (1749)
4) 37–55 (1055) 57–59 (721)
01/1766) 68–71 (185/169) 66 (583)
 (1450) 38–39 (2666)a 60 (377)
428  b r a z j i n f e c t d i s . 2 0 1 4;1  8(4):421–433
70
60
50
Pe
rc
e
n
ta
ge
 o
f r
es
ita
nt
 is
ol
at
es
40
30
18
41
44
55
20
NR
58
69
20
31
20
9
16
28
30
38
9
15
33
10
0
Colombia Dominican
Republic
Ecuador
E. coli K. pneumoniae
 El Salvador Guatemala Honduras Panama Paraguay Peru
Fig. 4 – Findings of the Pan-American Health Organization (PAHO) summarizing the frequency of nosocomial Escherichia coli
009.35and Klebsiella pneumoniae isolates resistant to cefepime in 2
Klebsiella spp. exhibited unacceptably low susceptibility rates
to cephalosporins in all four countries (40–67%). The suscep-
tibilities of E. coli and Klebsiella spp. were modestly higher to
cefepime than to third-generation cephalosporins.33
In agreement with SENTRY, a consolidated 2009 network
analysis involving 14 hospitals in Chile revealed that 78%
and 79% of E. coli blood and urine cultures, respectively, were
susceptible to cefotaxime.55 Remarkable susceptibility rates
were observed for carbapenems (≥99.9%) while susceptibil-
ity rates were ≥90% for piperacillin/tazobactam and amikacin
and lower for ciproﬂoxacin (61–64%).55
Surveillance was conducted in 2006–2008 by the Colombian
Nosocomial Resistance Study Group, consisting of 14 tertiary-
care hospitals in seven major cities.56 Among E. coli isolates
from general wards (N > 2300 each year) and adult ICUs (N > 550
each year), resistance to third-generation cephalosporins was
low and stable at rates ranging from 2% to 8%. Among iso-
lates from adult ICUs, resistance to cefepime was also stable
at 4–5% during this period. For K. pneumoniae, resistance rates
to third-generation cephalosporins (ceftazidime and ceftria-
xone) among isolates from general wards were 19–20% in 2006
(N = 948); 24–29% in 2007 (N = 1244), and 15% in 2008 (N = 1038).
Among K. pneumoniae isolates from adult ICUs, resistance to
third-generation cephalosporins was 24–25% in 2006 (N = 497),
20–31% in 2007 (N = 800), and 9–24% in 2008 (N = 602). Among
isolates from adult ICUs, resistance to cefepime was 12% in
2006, 18% in 2007, and 11% in 2008.56
In the independent cohort studies that reported quan-
titative susceptibility data on Enterobacteriaceae harboring
ESBLs, co-resistance to multiple commonly used antimicrobial
agents besides resistance to third-generation cephalosporins
was evident.37–39,52 Moderate to high resistance rates (>15%
to <81%) were observed for aminoglycosides, trimethoprim/NR, not reported.
sulfamethoxazole, piperacillin/tazobactam, and quinolones,
whereas low resistance rates (<10%) were observed for car-
bapenems and tigecycline.37–41,52
Risk  factors
Studies conducted in locations throughout the world have
identiﬁed multiple risk factors for infection with ESBL-
producing Enterobacteriaceae in hospitalized patients.57–61 In
multivariate analyses in these studies, the following risk
factors were identiﬁed: previous antibiotic use (speciﬁcally,
quinolones,59 cephalosporins,57 oxyimino-cephalosporins,58
piperacillin/tazobactam,57 or -lactams with an oxyimino
group60), recurrent infections,59 hemodialysis,61 urinary
catheterization,58 artiﬁcial nutrition,59 and residence in a
nursing home.61
There are few studies of risk factors for ESBL-producing
Enterobacteriaceae in Latin America. Potential risk factors for
the occurrence of invasive infections arising from ESBL- and
non-ESBL-producing E. coli and Klebsiella spp. were assessed in
an international, prospective, observational study conducted
by the SENTRY Antimicrobial Surveillance Program, which
included 11 Latin American hospitals, from 2001–2002.62
Although underlying comorbidities and potential risk factors
were generally similar between ESBL and non-ESBL cases, a
higher proportion of ESBL cases had a gastrostomy or jejunos-
tomy tube (30.3% vs. 6.7%, p = 0.008), required ventilation
assistance (64.8% vs. 38.2%, p = 0.005), or had been admitted
to ICU (65.6% vs. 41.0%, p = 0.006) compared with non-ESBL
cases.62
Among single-center studies, multivariate analysis of ret-
rospective case-control data (n = 121 patients) pertaining to
 2 0 1 
a
1
o
p
p
c
d
c
a
a
K
L
c
i
D
S
p
h
p
A
S
c
s
b
c
p
w
s
p
e
a
C
t
t
e
4
g
a
n
h
B
s
a
r
h
n
E
h
c
a
o
c
d
c
ob r a z j i n f e c t d i s .
ll episodes of K. pneumoniae bacteremia for the period
993–2002 in a Mexican referral center revealed prior use
f cephalosporins (Odds ratio [OR] 7.6, 95% CI 1.1–53.5;
 = 0.039) and admission to ICU (OR 5.6, 95% CI 1.1–27.9;
 = 0.033) as signiﬁcant risk factors.63 Use of broad-spectrum
ephalosporins also featured as the only independent pre-
ictor of ESBL-producing enterobacteriaceae strains (n = 90)
ausing bacteremia in a recently published Mexican study,64
nd use of third-generation cephalosporins (p = 0.008) was
 risk factor for colonization of ESBL-producing strains of
lebsiella spp in a pediatric ICU in Brazil in 2008.65 Another
atin American study found a relationship between use of
iproﬂoxacin and prevalence of ESBL-producing K. pneumoniae
n a hospital setting.66
iscussion
ince the ﬁrst cases and outbreaks of infections by ESBL-
roducing Enterobacteriaceae were reported in Latin American
ospitals, there has been a steady increase in the overall
revalence and in the number of types of ESBLs detected.
ccording to region-wide surveillance data (ie, SENTRY, TEST,
MART, PAHO, and API) and ﬁndings from independent
ountry-speciﬁc cohort studies, ESBL production among Kleb-
iella spp. can be considered endemic in Latin America. The
alance of data indicates that rates of nosocomial infection
aused by ESBL-producing Enterobacteriaceae,  particularly K.
neumoniae, are high in Latin America compared with other
orld regions (Fig. 1). More  speciﬁcally, there has been a rapid
pread of CTX-M enzymes throughout Latin American hos-
itals, which has been facilitated by horizontal transfer of
ncoding plasmids and successful clones. While we observed
 geographical trend in the prevalence of a ﬁnite number of
TX-M enzyme subtypes in Latin America (i.e CTX-M-15 in
he North; CTX-M-2 in the South), there was clear evidence
hat this regional association is weakening as CTX-Ms become
ven more  widespread and evolve locally.
In surveillance data reviewed for this article (Table 3),
5–53% of K. pneumoniae isolates are nonsusceptible to third-
eneration cephalosporins, compared with 21–27% resistance
ssociated with K. pneumoniae HAIs in the United States.67 The
orthern countries of Guatemala, Honduras, and Mexico have
igh rates of cephalosporin-resistant E. coli, while Argentina,
razil, Colombia, and Panama have lower rates. For Kleb-
iella spp., Argentina, Brazil, Chile, Guatemala, and Honduras
re experiencing especially high rates of cephalosporin-
esistant strains, while Colombia, Panama, and Venezuela
ave lower rates. Independent cohort data showed that it is
ot uncommon in Latin America to encounter ESBL-producing
nterobacteriaceae that are nonsusceptible to cefepime, exhibit
igh rates of resistance to ﬂuoroquinolones and ampi-
illin/sulbactam, and have appreciable rates of resistance to
minoglycosides and piperacillin/tazobactam. Susceptibility
f ESBL-producing Enterobacteriaceae to the carbapenems, tige-
ycline, and colistin remains much higher (>90%).There are many  possible explanations for the observed
ifferences between countries and regions. Reported sus-
eptibility rates may have differed because of selection
f centers (public versus private) or other biases in study4;1 8(4):421–433 429
design, small numbers of isolates collected in some settings,
differing laboratory methods, or quality control in some
laboratories. Reported resistance rates may also reﬂect real
differences in prevalence of resistant pathogens arising from
local outbreaks, differences in antimicrobial prescribing
practices (including use of cephalosporins), differences in
facilities (e.g., rooms with multiple beds or overcrowded
conditions), and local infection control measures (or the lack
thereof). Unfortunately there are no studies that systemat-
ically investigate these differences between countries and
facilities in Latin America and their effect on prevalence
of ESBL-producing pathogens. Surveillance data must also
be read carefully because some sources report resistance
rates, while others report susceptibility rates—and because
nonsusceptibility is not the same as resistance. Furthermore,
data may over-represent tertiary care hospitals with more
complicated patient populations receiving more  intensive
care than the general hospital population.
The expanding geographic spread of ESBL-producing
Enterobacteriaceae in the community and hospital setting
underscores the importance of clinical and microbiologic
recognition of these enzymes at multiple levels of health care.
Surveillance data collected regionally in Latin America may
be used to guide empiric treatment of patients suspected of
multidrug-resistant infection, based on their individual risk
level. For example, it has been shown that patients with age 65
years or older, recent use of antibiotics, recent hospitalization
or stay in long-term care facility, and male sex have a greater
likelihood of infection by ESBL-producing Enterobacteriaceae;24
such patients may be suspected of infection with resistant
pathogens and treated accordingly. However, knowledge of
regional surveillance data and patient risk level is not ade-
quate to guide optimal choice of therapy. Physicians should
be aware of local data regarding the prevalence and antimicro-
bial susceptibilities of ESBL-producing bacterial strains in their
particular city and hospital, information that can help guide
treatment choices for patients in a particular facility. When
possible, pathogen identiﬁcation (at the genus and species
level) and information about the in vitro antimicrobial resis-
tance proﬁle of the pathogen infecting the individual patient
can guide the choice and adjustment of antimicrobials dur-
ing the course of treatment.68 Prospective observational data
have shown that patients have a survival advantage when
the correct antimicrobial agent is chosen as initial therapy
rather than empiric agents that provide no coverage against
the responsible pathogen.69
Collaborative institutional, local, national, and regional
surveillance of ESBL-producing Enterobacteriaceae is required
to assist diagnosis, support treatment decisions, and guide
antimicrobial stewardship and infection control efforts.68
The US Clinical and Laboratory Standards Institute (CLSI)
and the UK Health Protection Agency (HPA) have pub-
lished guidelines for the detection of ESBL-producing
organisms.70 Following PAHO surveillance system recom-
mendations, CLSI guidelines are followed in most Latin
American countries to detect the presence of ESBL-mediated
resistance. The difﬁculty in detecting and classifying spe-
ciﬁc ESBLs in the local setting is demonstrated by the
fact that hundreds of different ESBLs have been described,
including more  than 145 -lactamases in the CTX-M class
i s . 2 0
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alone (http://www.lahey.org/studies/other.asp). More than 890
unique protein sequences for -lactamases were determined
by late 2009.16 However, ﬁndings from Latin American stud-
ies show that molecular biology techniques can be useful
in characterizing virulent K. pneumoniae clones isolated from
patients and health care workers.21,71,72 The technology to
identify genes conferring resistance is improving quickly and
is becoming more  automated. Ideally, surveillance programs
in cities and hospitals should provide real-time information
about phenotype and mechanism of resistance in a rapid,
accurate, and reproducible manner.
Antimicrobial stewardship in conjunction with local
surveillance is also required to preserve the antimicrobial
integrity of a limited arsenal of agents. More  research is
required to elucidate the risk factors for acquiring ESBL-
producing Enterobacteriaceae,  although it can be stated that
antimicrobial treatment is the primary cause. Encouragingly,
a 2002–2006 study in Colombia showed that restriction of
third-generation cephalosporins can result in signiﬁcant (5-
fold) reduction in the number of ESBL-producing isolates.73
However, treatment with cefepime is not recommended in
areas where there is a high prevalence of circulating CTX-
Ms since clinical failures often result in patients with high
inoculum infections.72 Carbapenems are a treatment of choice
for infections caused by ESBL-producing Enterobacteriaceae,  but
an undesirable consequence of their use may be selection
of carbapenem-resistant non-fermenter Gram-negative bacilli
and Enterobacteriaceae.72,74–76 Instructions on how to restrict
and cycle certain antimicrobial agents for speciﬁc indications,
framed within a real-time surveillance-based drug formulary,
offer the best conditions for rational drug use.
Patient-to-patient transmission of ESBL-producing
pathogens has been reported; this is likely a more  important
mode of infection with K. pneumoniae than with E. coli.77,78
However, this issue has not been studied in Latin America
beyond nosocomial outbreaks. Because of difﬁculties with
infection control, patient-to-patient transmission could play
an important role in Latin American healthcare institutions.
Therefore, infection control efforts are crucial in reducing the
prevalence of drug-resistant pathogens. Local outbreaks of
ESBL-producing Klebsiella spp. strains have been successfully
addressed in Latin American settings through standard
infection control practices, including disinfection of the unit,
re-enforcing hand hygiene and barrier control measures, and
adjusting antimicrobial prescribing practices.21,72,79
In summary, the problem of high infection rates by ESBL-
producing Enterobacteriaceae in hospitals of Latin America
is exacerbated by the spread of multidrug-resistant strains.
Antimicrobial surveillance at the unit, hospital, city, national,
and regional level is recommended to guide decision making
about infection control efforts and appropriate antimicrobial
treatment.
Conﬂicts  of  interestManuel Guzmán Blanco is or has been a member of advisory
boards of Merck, Pﬁzer, Becton and Dickinson. He has received
research funds from Pﬁzer, Merck, Glaxo and Novartis. Jaime A.
Labarca has been a member of advisory boards of Merck Sharp 1 4;1  8(4):421–433
& Dhome and Pﬁzer, has received research funds from Merck
Sharp & Dhome, and has participated in clinical studies for
Sanoﬁ Pasteur. Maria Virginia Villegas has been a member of
advisory boards of Merck and Pﬁzer and has received research
funds from Pﬁzer, Merck, Novartis, AstraZeneca, Merck S.A,
Bayer, Janssen Cilag and Biomeriux. Eduardo Gotuzzo has been
a consultant to Pﬁzer and has received research funds from
Johnson & Johnson.
Acknowledgements
This publication was funded by Pﬁzer Inc. Medical writing sup-
port was provided by Malcolm Darkes and Lisa Baker of Engage
Scientiﬁc Solutions and was funded by Pﬁzer Inc.
Appendix  A.
Latin America Working Group on Bacterial Resistance:
Carlos Alvarez (Hospital Universitario San Ignacio and
Pontiﬁcia Universidad Javeriana, Bogotá, Colombia), Luis
Bavestrello (Clinica Ren˜aca, Vin˜a Del Mar, Chile), Eitan Berezin
(Santa Casa de São Paulo School of Medicine, Brazil), Eduardo
Gotuzzo (Universidad Peruana Cayetano Heredia, Lima, Peru),
Manuel Guzmán-Blanco (Hospital Privado Centro Médico de
Caracas, Venezuela), Jaime A. Labarca (Pontiﬁcia Universidad
Católica de Chile, Santiago, Chile), Carlos M.  Luna (Hospi-
tal de Clínicas José de San Martin Hospital, Universidad de
Buenos Aires, Argentina), Carlos Mejía (Hospital Roosevelt,
Guatemala City, Guatemala), Simone Nouer (Hospital Univer-
sitário Clementino Fraga Filho, Rio de Janeiro, Brazil), Eduardo
Rodríguez-Noriega (Hospital Civil de Guadalajara Fray Antonio
Alcalde, Guadalajara, Mexico), Mauro José Costa Salles (Hospi-
tal Irmandade da Santa Casa de Misericórdia de São Paulo,
Brazil), Carlos Seas (Universidad Peruana Cayetano Heredia,
Lima, Peru), Fortino Solórzano Santos (Hospital de Pediatría
Centro Médico Nacional Siglo XXI, Mexico City, Mexico), Maria
Virginia Villegas (International Center for Medical Research
and Training [CIDEIM], Cali, Colombia), Jeannete Zurita (Hospi-
tal Vozandes and Pontiﬁcia Universidad Católica del Ecuador,
Quito, Ecuador).
 e  f  e  r  e  n  c  e  s
1. World Health Organization. Report on the burden of endemic
health care-associated infection worldwide; 2011. Available at
http://whqlibdoc.who.int/publications/2011/9789241501507
eng.pdf [accessed 20.12.11].
2. European Centre for Disease Prevention and Control. Annual
epidemiological report Reporting on 2009 surveillance data
and  2010 epidemic intelligence data; 2011. Available at http://
www.ecdc.europa.eu/en/publications/Publications/Forms/
ECDC DispForm.aspx?ID=767 [accessed 17.07.12].
3.  Allegranzi B, Bagheri Nejad S, Combescure C, et al. Burden of
endemic health-care-associated infection in developing
countries: systematic review and meta-analysis. Lancet.
2011;377:228–41.
4. Vincent JL, Rello J, Marshall J, et al. International study of the
prevalence and outcomes of infection in intensive care units.
JAMA. 2009;302:2323–9.
 2 0 1 
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3b r a z j i n f e c t d i s .
5. Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative
bacteria: the dawn of the post-antibiotic era? Int J Antimicrob
Agents. 2007;29:630–6.
6. Savard P, Perl TM. A call for action: managing the emergence
of multidrug-resistant Enterobacteriaceae in the acute care
settings. Curr Opin Infect Dis. 2012;25:371–7.
7. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME.
Tigecycline for the treatment of multidrug-resistant
Enterobacteriaceae: a systematic review of the evidence from
microbiological and clinical studies. J Antimicrob Chemother.
2008;62:895–904.
8. Mendes RE, Rhomberg PR, Bell JM, Turnidge JD, Sader HS.
Doripenem activity tested against a global collection of
Enterobacteriaceae, including isolates resistant to other
extended-spectrum agents. Diagn Microbiol Infect Dis.
2009;63:415–25.
9. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and
antimicrobial resistance pattern comparisons among
bloodstream infection isolates from the SENTRY
Antimicrobial Surveillance Program (1997–2002). Diagn
Microbiol Infect Dis. 2004;50:59–69.
0. Andrade SS, Sader HS, Jones RN, Pereira AS, Pignatari AC,
Gales AC. Increased resistance to ﬁrst-line agents among
bacterial pathogens isolated from urinary tract infections in
Latin America: time for local guidelines? Mem Inst Oswaldo
Cruz. 2006;101:741–8.
1. Casellas JM. Resultados encuesta número 7. Rev Panam
Infectol. 2006;8:48–51.
2. Casellas JM. Resistencia a los antibacterianos en América
Latina: consecuencias para la infectología. Rev Panam Salud
Publica. 2011;30:519–28.
3. Gales AC, Sader HS, Jones RN. Urinary tract infection trends in
Latin American hospitals: report from the SENTRY
antimicrobial surveillance program (1997–2000). Diagn
Microbiol Infect Dis. 2002;44:289–99.
4. Guzmán-Blanco M, Casellas JM, Sader HS. Bacterial resistance
to  antimicrobial agents in Latin America. The giant is
awakening. Infect Dis Clin North Am. 2000;14:67–81.
5. Paterson DL, Bonomo RA. Extended-spectrum
beta-lactamases: a clinical update. Clin Microbiol Rev.
2005;18:657–86.
6. Bush K, Jacoby GA. Updated functional classiﬁcation of
beta-lactamases. Antimicrob Agents Chemother.
2010;54:969–76.
7. Casellas JM, Quinteros MG. A Latin American “point de vue”
on  the epidemiology, control, and treatment options of
infections caused by extended-spectrum beta-lactamase
producers. In: Amabile-Cuevas CF, editor. Antimicrobial
resistance in bacteria. Wymondham: Horizon Bioscience;
2006.
8. Canton R, Coque TM. The CTX-M beta-lactamase pandemic.
Curr Opin Microbiol. 2006;9:466–75.
9. Casellas JM, Goldberg M. Incidence of strains producing
extended spectrum beta-lactamases in Argentina. Infection.
1989;17:434–6.
0. Gonzalez-Vertiz A, Alcantar-Curiel D, Cuauhtli M, et al.
Multiresistant extended-spectrum beta-lactamase-producing
Klebsiella pneumoniae causing an outbreak of nosocomial
bloodstream infection. Infect Control Hosp Epidemiol.
2001;22:723–5.
1. Otman J, Cavassin ED, Perugini ME, Vidotto MC. An outbreak
of  extended-spectrum beta-lactamase-producing Klebsiella
species in a neonatal intensive care unit in Brazil. Infect
Control Hosp Epidemiol. 2002;23:8–9.
2. Sader HS, Gales AC, Pfaller MA, et al. Pathogen frequency and
resistance patterns in Brazilian hospitals: summary of results
from three years of the SENTRY Antimicrobial Surveillance
Program. Braz J Infect Dis. 2001;5:200–14.
34;1 8(4):421–433 431
3. Turner PJ. Extended-spectrum beta-lactamases. Clin Infect
Dis. 2005;4 41 Suppl.:S273–5.
4. Ben-Ami R, Rodríguez-Ban˜o J, Arslan H, et al. A multinational
survey of risk factors for infection with extended-spectrum
beta-lactamase-producing Enterobacteriaceae in
nonhospitalized patients. Clin Infect Dis. 2009;49:
682–90.
5. Quinteros M, Radice M, Gardella N, et al. Extended-spectrum
beta-lactamases in enterobacteriaceae in Buenos Aires,
Argentina, public hospitals. Antimicrob Agents Chemother.
2003;47:2864–7.
6. Villegas MV, Correa A, Perez F, et al. CTX-M-12 beta-lactamase
in  a Klebsiella pneumoniae clinical isolate in Colombia.
Antimicrob Agents Chemother. 2004;48:629–31.
7. Rossi F, Baquero F, Hsueh PR, et al. In vitro susceptibilities of
aerobic and facultatively anaerobic Gram-negative bacilli
isolated from patients with intra-abdominal infections
worldwide: 2004 results from SMART (Study for Monitoring
Antimicrobial Resistance Trends). J Antimicrob Chemother.
2006;58:205–10.
8. Baquero F, Hsueh PR, Paterson DL, et al. In vitro
susceptibilities of aerobic and facultatively anaerobic
gram-negative bacilli isolated from patients with
intra-abdominal infections worldwide: 2005 results from
Study for Monitoring Antimicrobial Resistance Trends
(SMART). Surg Infect (Larchmt). 2009;10:99–104.
9. Villegas MV, Blanco MG, Sifuentes-Osornio J, Rossi F.
Increasing prevalence of extended-spectrum-beta-lactamase
among Gram-negative bacilli in Latin America—2008 update
from the Study for Monitoring Antimicrobial Resistance
Trends (SMART). Braz J Infect Dis. 2011;15:34–9.
0. Hawser SP, Bouchillon SK, Hoban DJ, et al. Low frequency of
ertapenem-resistant intra-abdominal isolates of
Escherichia coli from Latin America: susceptibility,
ESBL-occurrence, and molecular characterisation (SMART
2008–2009). J Chemother. 2012;24:6–11.
1. Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ.
Antimicrobial susceptibility among organisms from the
Asia/Paciﬁc Rim, Europe and Latin and North America
collected as part of TEST and the in vitro activity of
tigecycline. J Antimicrob Chemother. 2007;60:1018–29.
2. Fernández-Canigia L, Dowzicky MJ. Susceptibility of
important Gram-negative pathogens to tigecycline and other
antibiotics in Latin America between 2004 and 2010. Ann Clin
Microbiol Antimicrob. 2012;11:29.
3. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial
resistance among Gram-negative bacilli isolated from Latin
America: results from SENTRY Antimicrobial Surveillance
Program (Latin America, 2008–2010). Diagn Microbiol Infect
Dis. 2012;73:354–60.
4. Pan-American Health Organization. Informe Anual de la Red
de Monitoreo/Vigilancia de la Resistencia a los Antibióticos –
2006; 2006. Available at http://www2.paho.org/hq/
dmdocuments/2009/amr 2006 informe anual.pdf [accessed
06.03.13].
5.  Pan-American Health Organization. Informe Anual de la Red
de Monitoreo/Vigilancia de la Resistencia a los
Antibióticos/2009; 2009. Available at http://new.paho.org/hq/
index.php?option=com content&view=article&id=6221&
Itemid=4328&lang=en [accessed 06.03.13].
6. Hoban DJ, Nicolle LE, Hawser S, Bouchillon S, Badal R.
Antimicrobial susceptibility of global inpatient urinary tract
isolates of Escherichia coli: results from the Study for
Monitoring Antimicrobial Resistance Trends (SMART)
program: 2009–2010. Diagn Microbiol Infect Dis.
2011;70:507–11.
7. Gaitan CS, Espinal MP. Molecular characterization of
extended-spectrum beta-lactamases-producing Escherichia coli
i s . 2 0
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6432  b r a z j i n f e c t d 
and Klebsiella pneumoniae in hospitals of the Caribean Region.
Colombia Rev Chilena Infectol. 2009;26:239–46.
8. Garza-Gonzalez E, Mendoza Ibarra S.I., Llaca-Diaz JM,
Gonzalez GM. Molecular characterization and antimicrobial
susceptibility of extended-spectrum {beta}-lactamase-
producing Enterobacteriaceae isolates at a tertiary-care centre
in  Monterrey. Mexico J Med Microbiol. 2011;60:84–90.
9. Morﬁn-Otero R, Mendoza-Olazaran S, Silva-Sanchez J, et al.
Characterization of Enterobacteriaceae isolates obtained from a
tertiary care hospital in Mexico, which produces
extended-spectrum beta-lactamase. Microb Drug Resist. 2013.
0. Marcano D, De Jesús A, Hernández L, Torres L. Frequency of
enzymes associated with reduced sensitivity to beta-lactam
antibiotics in enterobacteria isolates, Caracas, Venezuela. Rev
Panam Salud Publica. 2011;30:529–34.
1. da Silva Dias RC, Borges-Neto AA, D’Almeida Ferraiuoli GI,
de-Oliveira MP, Riley LW, Moreira BM. Prevalence of AmpC and
other beta-lactamases in enterobacteria at a large urban
university hospital in Brazil. Diagn Microbiol Infect Dis.
2008;60:79–87.
2. Navarro-Navarro M, Robles-Zepeda RE, Garibay-Escobar A,
Ruiz-Bustos E. Hospital and community-acquired
beta-lactamases-producing Escherichia coli and Klebsiella
pneumoniae at hospitals in Hermosillo. Sonora Salud Publica
Mex. 2011;53:341–4.
3. Tedesco Maiullari RM, Guevara A. Enterobacteria producers of
extended-spectrum beta-lactamase in a hospital from
Venezuela. Infez Med. 2012;20:93–9.
4. Quin˜ones D, Valverde A, Rodriguez-Banos M, et al. High clonal
diversity in a non-outbreak situation of clinical ESBL-
producing Klebsiella pneumoniae isolates in the First National
Surveillance Program in Cuba. Microb Drug Resist. 2013.
5. Wollheim C, Guerra IM, Conte VD, et al. Nosocomial and
community infections due to class A extended-spectrum
beta-lactamase (ESBLA)-producing Escherichia coli and
Klebsiella spp. in southern Brazil. Braz J Infect Dis.
2011;15:138–43.
6. Nogueira Kda S, Higuti IH, do Nascimento AJ, et al.
Occurrence of extended-spectrum beta-lactamases in
Enterobacteriaceae isolated from hospitalized patients in
Curitiba, southern Brazil. Braz J Infect Dis. 2006;10:390–5.
7. Mena P, González AJC, Joseﬁna M. Extended spectrum
beta-lactamase detection in Enterobacteriaceae family
strains. Kasmera. 2009;37:25–37.
8. Sennati S, Santella G, Di Conza J, et al. Changing
epidemiology of extended-spectrum beta-lactamases in
Argentina: emergence of CTX-M-15. Antimicrob Agents
Chemother. 2012;56:6003–5.
9. Celenza G, Pellegrini C, Caccamo M, Segatore B, Amicosante
G,  Perilli M. Spread of bla(CTX-M-type) and bla(PER-2)
beta-lactamase genes in clinical isolates from Bolivian
hospitals. J Antimicrob Chemother. 2006;57:
975–8.
0. Poirel L, Naas T, Le Thomas I, Karim A, Bingen E, Nordmann P.
CTX-M-type extended-spectrum beta-lactamase that
hydrolyzes ceftazidime through a single amino acid
substitution in the omega loop. Antimicrob Agents
Chemother. 2001;45:3355–61.
1. Dropa M, Balsalobre LC, Lincopan N, et al. Extended-spectrum
beta-lactamases among Enterobacteriaceae isolated in a public
hospital in Brazil. Rev Inst Med Trop Sao Paulo. 2009;51:203–9.
2. Pulido IY, Mantilla JR, Valenzuela EM, Reguero MT, Gonzalez
EB.  Distribution of extended spectrum
beta-lactamases-codifying genes in Klebsiella pneumoniae
isolates from hospitals of Bogota, DC, Colombia. Biomedica.
2011;31:15–20.
3. Bello H, Trabal N, Ibanez D, et al. Beta-lactamases other than
TEM and SHV among strains of Klebsiella pneumoniae subsp 1 4;1  8(4):421–433
pneumoniae isolated from Chilean hospitals. Rev Med  Chil.
2005;133:737–9.
4. Casellas JM. Resultados de la 7a Encuesta del Comité de
Resistencia a Antimicrobianos de la Asociación
Panamericana de Infectología. Rev Panam Infectol. 2006;8:
48–55.
5. Silva FO, Cifuentes M, Pinto EC; representing the Collaborative
Group on Antimicrobial Resistance. Results of antimicrobial
susceptibility surveillance in Chile: consolidating a network.
Rev Chile Infect. 2011;28:19–27.
6. Bricen˜o DF, Correa A, Valencia C, et al. Antimicrobial
resistance of Gram negative bacilli isolated from tertiary-care
hospitals in Colombia. Biomedica. 2010;30:371–81.
7. Cohen-Nahum K, Saidel-Odes L, Riesenberg K, Schlaeffer F,
Borer A. Urinary tract infections caused by multi-drug
resistant Proteus mirabilis: risk factors and clinical outcomes.
Infection. 2010;38:41–6.
8. Wu UI, Yang CS, Chen WC,  Chen YC, Chang SC. Risk factors
for  bloodstream infections due to extended-spectrum
beta-lactamase-producing Escherichia coli.  J Microbiol
Immunol Infect. 2010;43:310–6.
9. Cassier P, Lallechere S, Aho S, et al. Cephalosporin and
ﬂuoroquinolone combinations are highly associated with
CTX-M beta-lactamase-producing Escherichia coli: a
case–control study in a French teaching hospital. Clin
Microbiol Infect. 2011;17:1746–51.
0. Paterson DL, Ko WC,  Von Gottberg A, et al. International
prospective study of Klebsiella pneumoniae bacteremia:
implications of extended-spectrum beta-lactamase
production in nosocomial Infections. Ann Intern Med.
2004;140:26–32.
1. Saely S, Kaye KS, Fairfax MR, Chopra T, Pogue JM.
Investigating the impact of the deﬁnition of previous
antibiotic exposure related to isolation of extended spectrum
beta-lactamase-producing Klebsiella pneumoniae.  Am J Infect
Control. 2011;39:390–5.
2. Bhavnani SM, Ambrose PG, Craig WA, Dudley MN, Jones RN.
Outcomes evaluation of patients with ESBL- and
non-ESBL-producing Escherichia coli and Klebsiella species as
deﬁned by CLSI reference methods: report from the SENTRY
Antimicrobial Surveillance Program. Diagn Microbiol Infect
Dis. 2006;54:231–6.
3. Mosqueda-Gómez JL, Montan˜o-Loza A, Rolón AL, et al.
Molecular epidemiology and risk factors of bloodstream
infections caused by extended-spectrum
beta-lactamase-producing Klebsiella pneumoniae A
case–control study. Int J Infect Dis. 2008;12:
653–9.
4. Muro S, Garza-Gonzalez E, Camacho-Ortiz A, et al. Risk
factors associated with extended-spectrum
beta-lactamase-producing Enterobacteriaceae nosocomial
bloodstream infections in a tertiary care hospital: a clinical
and  molecular analysis. Chemotherapy. 2012;58:
217–24.
5. Levy SS, Mello MJ, Gusmao-Filho FA, Correia JB. Colonisation
by extended-spectrum beta-lactamase-producing Klebsiella
spp. in a paediatric intensive care unit. J Hosp Infect.
2010;76:66–9.
6. Bermejo J, Bencomo B, Arnesi N, Lesnaberes P, Borda N,
Notario R. High relationship between ciproﬂoxacin use and
prevalence of ESBL Klebsiella pneumoniae.  Rev Chilena Infectol.
2006;23:316–20.
7. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update:
antimicrobial-resistant pathogens associated with
healthcare-associated infections: annual summary of data
reported to the National Healthcare Safety Network at the
Centers for Disease Control and Prevention, 2006–2007. Infect
Control Hosp Epidemiol. 2008;29:996–1011.
 2 0 1 
6
6
7
7
7
7
7
7
7
7
7b r a z j i n f e c t d i s .
8. O’Brien TF, Stelling J. Integrated multilevel surveillance of the
world’s infecting microbes and their resistance to
antimicrobial agents. Clin Microbiol Rev. 2011;24:281–95.
9. Alvarez-Lerma F. Modiﬁcation of empiric antibiotic treatment
in patients with pneumonia acquired in the intensive care
unit. ICU-Acquired Pneumonia Study Group. Intensive Care
Med. 1996;22:387–94.
0. Pitout JD, Laupland KB. Extended-spectrum
beta-lactamase-producing Enterobacteriaceae: an emerging
public-health concern. Lancet Infect Dis. 2008;8:159–66.
1. Andrade V, Silva J. Characterization of SHV-5
beta-lactamase-producing Klebsiella pneumoniae in an
intensive care unit. Salud Publica Mex. 2004;46:524–8.
2. Casellas JM, Nannini E, Radice M, et al. Estudio de un brote
debido a aislados de Klebsiella pneumoniae productores de
betalactamasas de espectro extendido en un centro
asistencial de Rosario - Argentina. Rev Panam Infectol.
2005;7:21–7.
3. Galvis CE, Marin˜oa AC, Monroy J, Posso YH. The impact of an
antibiotic restriction policy in the intensive care unit at the
hospital militar central. Rev Med. 2008:2008.
4. Furtado GH, Perdiz LB, Onita JH, Wey SB, Medeiros EA.
Correlation between rates of carbapenem consumption and
74;1 8(4):421–433 433
the prevalence of carbapenem-resistant Pseudomonas
aeruginosa in a tertiary care hospital in Brazil: a 4-year study.
Infect Control Hosp Epidemiol. 2010;31:664–6.
5. Zilberberg MD, Chen J, Mody SH, Ramsey AM, Shorr AF.
Imipenem resistance of Pseudomonas in pneumonia: a
systematic literature review. BMC Pulm Med. 2010;10:45.
6. Papadimitriou-Olivgeris M, Marangos M, Fligou F, et al. Risk
factors for KPC-producing Klebsiella pneumoniae enteric
colonization upon ICU admission. J Antimicrob Chemother.
2012;67:2976–81.
7. Harris AD, Kotetishvili M, Shurland S, et al. How important is
patient-to-patient transmission in extended-spectrum
beta-lactamase Escherichia coli acquisition. Am J Infect
Control. 2007;35:97–101.
8. Harris AD, Perencevich EN, Johnson JK, et al.
Patient-to-patient transmission is important in
extended-spectrum beta-lactamase-producing Klebsiella
pneumoniae acquisition. Clin Infect Dis. 2007;45:
1347–50.9. González ACR, Gil FG, Solórzano MR, et al. Outbreak of
multiresistant and extended spectrum -lactamase
producing Klebsiella pneumoniae in a high risk neonatal unit.
Rev Chil Infectol. 2011;28:28–34.
